Eli Lilly and Company (LLY)
Baron Opportunity Fund Q4 2025 Contributors And Detractors
SpaceX is generating significant value with the rapid expansion of its Starlink broadband service. Eli Lilly shares contributed to performance as Zepbound continues to gain share for the treatment of obesity. We decided to exit the Oracle position and book a short-term tax loss, spreading the capital across several of the investments listed above.
What Will Drive Eli Lilly Stock's Next Breakout?
Eli Lilly stock (NYSE: LLY) has been on a tear, surging over 60% in just the last six months. This momentum is part of a broader pattern of explosive growth; the stock has repeatedly rallied more than 30% in two-month windows, with standout gains exceeding 50% in both 2021 and 2025.
LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal
Eli Lilly is set to buy Orna Therapeutics for $2.4B to expand in vivo CAR-T and circular RNA capabilities, signaling a long-term push to diversify its pipeline.
Unlocking Lilly (LLY) International Revenues: Trends, Surprises, and Prospects
Explore how Lilly's (LLY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut
In its latest earnings report, Eli Lilly and Company NYSE: LLY once again showed why it has become by far one of the world's most valuable healthcare stocks. Year-to-date, Eli Lilly's market capitalization exceeds $900 billion.
Eli Lilly (LLY) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Eli Lilly: Positives Outweigh The Concerns
Eli Lilly and Company's price jump following its latest earnings release is completely justified going by both the performance and guidance. Both LLY revenue and EPS growth exceeded guidance, despite a cut in Zepbound's price in Q4 2025. The guidance for 2026 also makes the stock attractive. However, a fuller impact of price cuts is expected to be visible only a quarter later, along with a possible impact of an acquisition on its earnings, indicating some caution is warranted for LLY stock.
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
The first week of February 2026 will be remembered as the day the pharmaceutical sector's most famous partnership officially dissolved. For years, Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S NYSE: NVO traded in lockstep, their stock charts nearly identical as they raced to supply the world with weight-loss medicines.
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions
There's a growing divergence between the shares of rival weight-loss drugmakers Eli Lilly and Novo Nordisk.
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions
There's a growing divergence between the shares of rival weight-loss drugmakers Eli Lilly and Novo Nordisk.
